BrainsWay (BWAY) announced that Highmark Blue Cross Blue Shield has released a draft medical policy which, among other developments, expands coverage to include adolescent and adult patients with major depressive disorder, MDD, treated with the company’s accelerated Deep TMS protocol. The policy, which is anticipated to go into effect in February 2026 after an open comment period, will provide coverage of BrainsWay’s accelerated SWIFT protocol, which consists of an acute phase of five treatment sessions per day for six days, followed by two sessions per day once a week for four weeks, for a total of 38 sessions.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- BrainsWay Highlights FDA Approval of Neurolief’s At-Home Proliv Rx Device for Treatment-Resistant Depression
- Brainsway announces U.S. FDA granted PMA for Neurolief’s ProlivRx system
- BrainsWay Wins First Insurer Coverage for Accelerated Deep TMS Depression Protocol
- Brainsway announces first coverage policy for accelerated Deep TMS
- BrainsWay Wins Optum Coverage Expansion for Adolescent Deep TMS Depression Therapy